About this trial
This trial is to demonstrate improvement in clinical efficacy of tisotumab vedotin compared to chemotherapy in subjects with 2L-3L cervical cancer.
Patient Profile
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Patients with recurrent/metastatic cervical cancer
(r/mCC) who have received 1 or 2 prior lines of chemotherapy
Where’s this trial being run?
University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | innovaTV 301 / ENGOT cx12 |
|---|---|
| Number: | 19-02 |
| Full Title: | A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second or Third-Line Recurrent or Metastatic Cervical Cancer |
| Principal Investigator: | Dr Paula Calvert |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Seagen Inc. |
| Recruitment Started: |
Global: February 2021 Ireland: November 2022 |
| Global Recruitment Target: | 486 |
|---|---|
| Ireland Recruitment Target: | 20 |